Drug Approval | September 30, 2023
Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
WINLEVI works differently from any other topical acne treatment
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams
Commenced operations in flood-affected Himachal Pradesh
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated
